

1 **Long-term and serious harms of medical cannabis and cannabinoids for chronic pain: A**
2 **systematic review of non-randomized studies**

3

- 4 Dena Zeraatkar, *methodologist*
5 *Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON*
6 *Department of Biomedical Informatics, Harvard Medical School, Boston, MA*
- 7 Matthew Adam Cooper, *medical student*
8 *Michael G. Degroote School of Medicine*
9 *McMaster University, Hamilton, ON*
- 10 Arnav Agarwal, *resident physician*
11 *Department of Medicine*
12 *University of Toronto, Toronto, ON*
- 13 Robin W. M. Vernooij, *methodologist*
14 *Netherlands Comprehensive Cancer Organization (IKNL)*
15 *Utrecht, the Netherlands*
- 16 Gareth Leung, *methodologist*
17 *Department of Public Health and Primary Care,*
18 *University of Cambridge, Cambridge, UK*
- 19 Kevin Loniewski, *nursing student*
20 *Faculty of Health, Seneca College, King City, ON.*
21 *York University, Toronto, ON*
- 22 Jared E. Dookie, *medical student*
23 *Schulich School of Medicine and Dentistry*
24 *Western University, London, ON*
- 25 Muhammad Muneeb Ahmed, *medical student*
26 *Michael G. Degroote School of Medicine*
27 *McMaster University, Hamilton, ON*
- 28 Brian Younho Hong, *resident physician*
29 *Division of Plastic and Reconstructive Surgery*
30 *University of Toronto, Toronto, ON*
- 31 Chris J. Hong, *resident physician*
32 *Department of Otolaryngology-Head & Neck Surgery*
33 *University of Toronto, Toronto, ON*
- 34 Patrick Jiho Hong, *resident physician*
35 *Department of Anesthesiology and Pain Medicine*
36 *University of Toronto, Toronto, ON*
- 37 Rachel Couban, *medical librarian*
38 *Department of Anesthesia*
39 *Department of Health Research Methods, Evidence, and Impact*
40 *McMaster University, Hamilton, ON*
- 41 Thomas Agoritsas, *assistant professor*
42 *Department Medicine, University Hospitals of Geneva, Geneva, Switzerland*
43 *Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON*
- 44 Jason W. Busse, *associate professor**
45 *Department of Anesthesia*
46 *Department of Health Research Methods, Evidence, and Impact*
47 *McMaster University, Hamilton, ON*
48 *bussejw@mcmaster.ca*
- 49

50 *Corresponding author

51 **Running head:** Harms of medical cannabis

52 **Abbreviations:** Cochrane Central Register of Controlled Trials (CENTRAL), Palmitoylethanolamide (PEA),
53 tetrahydrocannabinol (THC)

54 **Keywords:** Medical cannabis, chronic pain, adverse events, harms, non-randomized studies,
55 observational studies

56 **Disclaimers:** None.

57 **Funding:** DZ is supported by a Banting Postdoctoral Fellowship.

58 **Ethics approval:** The systematic review is exempt from ethics approval.

59 **Data:** Data will be made available upon publication: <https://osf.io/ut36z/>

60 **Acknowledgements:** We thank the members of the Rapid Recommendations panel for critical feedback
61 on the selection of the adverse events of interest. We thank James MacKillop, PhD, for his help with the
62 interpretation of problematic cannabis use, abuse, dependence and withdrawal syndrome within
63 studies.

64 **Authors' Contributions:** JWB and TA conceived the idea. RC designed and conducted the search. DZ,
65 MAC, AA, GL, KL, JD, BYH, CH, and PJH screened search records, extracted data, and assessed the risk of
66 bias of the eligible studies. DZ conducted analyses. DZ, JWB, and TA interpreted the data. DZ wrote the
67 first draft of the manuscript. JWB and TA critically revised the manuscript. All authors reviewed and
68 approved the final version. DZ and JWB are the guarantors.

69
70 * I, the Submitting Author, have the right to grant and does grant on behalf of all authors of the Work
71 (as defined in the author licence), an exclusive licence and/or a non-exclusive licence for contributions
72 from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply,
73 and/or iii) in accordance with the terms applicable for US Federal Government officers or employees
74 acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ
75 Publishing Group Ltd ("BMJ") its licensees.

76

77 Word count: 5,170

78 **Abstract**

79 **Objective:** To establish the risk and prevalence of long-term and serious harms of medical cannabis and
80 cannabinoids for chronic pain.

81 **Design:** Systematic review and meta-analysis.

82 **Data sources:** MEDLINE, EMBASE, PsycInfo, and the Cochrane Central Register of Controlled Trials
83 (CENTRAL) from inception to April 1, 2020.

84 **Study selection:** Non-randomized studies reporting on harms of medical cannabis or cannabinoids in
85 people living with chronic pain with ≥ 4 weeks of follow-up.

86 **Data extraction and synthesis:** A parallel guideline panel provided input on the design and
87 interpretation of the systematic review, including selection of adverse events for consideration. Two
88 reviewers, working independently and in duplicate, screened the search results, extracted data, and
89 assessed risk of bias. We used random-effects models for all meta-analyses and the GRADE approach to
90 evaluate the certainty of evidence.

91 **Results:** We identified 39 eligible studies that enrolled 12,143 patients with chronic pain. Very low
92 certainty evidence suggests that adverse events are common (prevalence: 26.0%; 95% CI 13.2 to 41.2)
93 among users of medical cannabis or cannabinoids for chronic pain, particularly any psychiatric adverse
94 events (prevalence: 13.5%; 95% CI 2.6 to 30.6). However, very low certainty evidence indicates serious
95 adverse events, adverse events leading to discontinuation, cognitive adverse events, accidents and
96 injuries, and dependence and withdrawal syndrome are uncommon and typically occur in fewer than
97 one in 20 patients. We compared studies with < 24 weeks and ≥ 24 weeks cannabis use and found more
98 adverse events reported among studies with longer follow-up (test of interaction $p < 0.01$).
99 Palmitoylethanolamide was usually associated with few to no adverse events. We found insufficient
100 evidence addressing the harms of medical cannabis compared to other pain management options, such
101 as opioids.

102 **Conclusions:** There is very low certainty evidence that adverse events are common among people living
103 with chronic pain who use medical cannabis or cannabinoids, but that few patients experience serious
104 adverse events. Future research should compare long-term and serious harms of medical cannabis with
105 other management options for chronic pain, including opioids.

106 Systematic review registration <https://osf.io/25bxf>

107 **What is already known on this topic**

- 108
- Medical cannabis and cannabinoids are increasingly used for the management of chronic pain.
- 109
- Clinicians and patients considering medical cannabis or cannabinoids as a treatment option for
- 110 chronic pain require evidence on benefits and harms, including long-term and serious adverse
- 111 events to make informed decisions.

112 **What this study adds**

- 113
- Very low certainty evidence suggests that adverse events are common among people living with
- 114 chronic pain who use medical cannabis or cannabinoids, including psychiatric adverse events,
- 115 though serious adverse events, adverse events leading to discontinuation, cognitive adverse
- 116 events, accidents and injuries, and dependence and withdrawal syndrome are uncommon.
- There is insufficient evidence comparing the harms of medical cannabis or cannabinoids to other
- 117 pain management options, such as opioids.
- 118

119

120

121 **Background**

122 Chronic pain is the primary cause of health care resource use and disability among working adults in
123 North America and Western Europe.^{1 2} The use of cannabis for the management of chronic pain is
124 becoming increasingly common due to pressure to reduce opioid use, increased availability and
125 changing legislation, shift in public attitudes and decreased stigma, and aggressive marketing.^{3 4} The two
126 most-studied cannabinoids in medical cannabis are delta-9-tetrahydrocannabinol (THC) and cannabidiol
127 (CBD).⁵ THC binds to cannabinoid receptors type 1 and 2, is an analog to the endogenous cannabinoid,
128 anandamide, and has shown psychoactive, analgesic, anti-inflammatory, antioxidant, antipruritic, anti-
129 spasmodic, and muscle-relaxant activities. CBD directly interacts with various ion channels to produce
130 analgesic, anti-inflammatory, anti-convulsant and anxiolytic activities, without the psychoactive effect of
131 THC.⁵ Use of cannabis for therapeutic purposes, however, remains contentious due to its known and
132 suspected harms.⁶⁻⁹

133 Though common adverse events caused by medical cannabis, including nausea, vomiting, headache,
134 drowsiness, and dizziness, have been well documented in randomized controlled trials and reviews of
135 randomized controlled trials,^{10 11} less is known about potentially uncommon but serious adverse events,
136 particularly events that may occur with longer durations of medical cannabis use, such as dependence,
137 withdrawal symptoms, and psychosis.^{4 12-17} Such adverse events are usually observed in large non-
138 randomized studies that recruit larger numbers of patients and typically follow them for longer
139 durations of time. Further, evidence from non-randomized studies may be more generalizable, since
140 randomized controlled trials typically use strict eligibility criteria.

141 The objective of this systematic review and meta-analysis is to summarize the evidence on the risks and,
142 when evidence on risk is not available, the prevalence of adverse events related to medical cannabis and
143 cannabinoids from non-randomized studies. This evidence synthesis is part of the *BMJ Rapid*
144 *Recommendations* project, a collaborative effort from the *MAGIC Evidence Ecosystem Foundation*
145 (www.magicevidence.org) and the *BMJ*.¹⁸ A guideline panel helped define the study question and
146 selected adverse events for review. The adverse events of interest include psychiatric and cognitive
147 adverse events, injuries and accidents, and dependence and withdrawal. It is one of four systematic
148 reviews that together informed a parallel guideline on medical cannabis and cannabinoids published on
149 bmj.com and the *MAGICapp*.^{11 19-21} A parallel systematic review addressed evidence from randomized
150 trials.¹¹

151

152 **Methods**

153 We report our systematic review in accordance with the PRISMA Harms Checklist.²² We registered the
154 protocol for our review at OSF (<https://osf.io/25bxf>).²²

155 ***Guideline panel involvement***

156 A guideline panel helped define the study question and selected the adverse events for review. The
157 panel included nine content experts (two general internists, two family physicians, a pediatrician, a
158 physiatrist, a pediatric anesthesiologist, a clinical pharmacologist, and a rheumatologist), nine
159 methodologists (five of whom are also front-line clinicians), and three people living with chronic pain
160 (one of whom used cannabinoids for medical purposes).

161 ***Patient and public involvement***

162 Three patient partners were included as part of the guideline panel and contributed to the selection and
163 prioritization of outcomes, protocol, and interpretation of review findings, and provided insight on
164 values and preferences.

165 ***Search***

166 A medical librarian searched MEDLINE, EMBASE, PsychInfo, and Cochrane Central Register of Controlled
167 Trials (CENTRAL) from inception to April 1, 2020, with no restrictions on language, for non-randomized
168 studies reporting on harms or adverse events of medical cannabis or cannabinoids for chronic pain
169 (Appendix 1). We scanned reference lists of relevant reviews to identify any eligible studies not retrieved
170 by our electronic search and solicited content experts from our panel for unpublished studies.

171 ***Study selection***

172 Reviewers, working independently and in duplicate, reviewed titles and abstracts of search records and
173 subsequently full texts of records found potentially eligible at the title and abstract screening stage.
174 Reviewers resolved disagreements by discussion or by adjudication by a third reviewer (DZ).

175 We included all non-randomized studies that reported on any patient-important harm or adverse event
176 associated with the use of any formulation of medical cannabis or cannabinoids in adults or children,
177 living with chronic pain (pain lasting for ≥ 3 months) or a medical condition associated with chronic pain

178 (i.e., fibromyalgia, arthritis, multiple sclerosis, neuropathy, inflammatory bowel disease, stroke, or
179 advanced cancer) or that compared adverse events associated with medical cannabis or cannabinoids
180 with another pharmacologic or non-pharmacologic intervention. Based on input from the guideline
181 panel, we excluded studies in which patients used cannabis for less than 4 weeks because we
182 anticipated that four weeks would be the minimum amount of time after which we would reasonably
183 expect to observe potential serious or long term harms associated with medical cannabis.²³ We looked
184 for explicit statements or evidence that patients were experiencing chronic pain. We excluded studies in
185 which: (1) fewer than 25 patients used medical cannabis or cannabinoids, (2) patients did not suffer
186 from chronic pain or a condition that commonly causes chronic pain or more than 20% of patients
187 reported using medical cannabis or cannabinoids for a condition other than chronic pain, (3) patients
188 were using medical cannabis for recreational reasons, (4) only surrogate measures of patient-important
189 harms and adverse effects (e.g., performance on cognitive tests, lab values) were reported, and (5)
190 systematic reviews and other types of studies that did not describe primary data.

191 ***Data extraction and risk of bias***

192 Reviewers, working independently and in duplicate and using a standardized and pilot-tested data
193 collection form, extracted the following information from each eligible study: (1) study design, (2)
194 patient characteristics (age, sex, condition/diagnosis), (3) characteristics of medical cannabis or
195 cannabinoids (name of product, dose, and duration), and (4) number of patients that experienced
196 adverse events, including all adverse events, serious adverse events, and withdrawal due to adverse
197 events. We classified adverse events as serious based on the classification used in primary studies. For
198 comparative studies, we collected results from models adjusted for confounders, when reported, and
199 unadjusted models when results for adjusted models were not reported.

200 When studies reported the number of events rather than the number of patients experiencing adverse
201 events, we only extracted the number of events if they were infrequent (the number of events
202 accounted for less than 10% of the total number of study participants). For studies that reported on
203 adverse events at multiple timepoints, we extracted data for the longest point of follow-up that
204 included, at minimum, 80% of the patients recruited into the study. Reviewers resolved disagreements
205 by discussion or by adjudication with a third reviewer (DZ).

206 We used the Cochrane-endorsed ROBINS-I tool to rate the risk of bias of studies as low, moderate,
207 serious, or critical across seven domains: (1) bias due to confounding, (2) selection of patients into the

208 study, (3) classification of the intervention, (4) bias due to deviations from the intended intervention, (5)
209 missing data, (6) measurement of outcomes, and (7) selection of reported results.²⁴ Appendix 2 presents
210 additional details on the assessment of risk of bias. Studies were rated at low risk of bias overall when all
211 domains were at low risk of bias; moderate risk of bias if all domains were rated at low or moderate risk
212 of bias; at serious risk of bias when all domains were rated either at low, moderate, or serious risk of
213 bias; and at critical risk of bias when one or more domains were rated as critical.

214 ***Data synthesis***

215 In this review, we synthesize data on serious adverse events and adverse events that may emerge with
216 longer duration of medical cannabis use for which data is typically not reported in randomized trials.
217 Identified by a parallel BMJ Rapid Recommendations guideline panel as important, these patient-
218 important outcomes included psychiatric and cognitive adverse events, injuries and accidents, and
219 dependence and withdrawal. Data on all other adverse events reported in primary studies are available
220 in an open-access database (<https://osf.io/ut36z/>).

221 Adverse events are reported as binary outcomes. For comparative studies, when possible, we present
222 risk differences and associated 95% confidence intervals (95% CIs). Since there were only two eligible
223 comparative studies each with different comparators, we did not perform meta-analysis. For single-arm
224 studies, we pooled the proportion of patients experiencing adverse events of interest by first applying a
225 Freeman-Tukey type arcsine square root transformation to stabilize the variance. Without this
226 transformation, very high or very low prevalence estimates can produce confidence intervals that
227 contain values lower than 0% or higher than 100%. All meta-analyses used DerSimonian-Laird random-
228 effects models, which are conservative as they consider both within- and between-study variability.²⁵⁻²⁷
229 We evaluated heterogeneity for all pooled estimates through visual inspection of forest plots and
230 calculation of tau-squared (τ^2), because some statistical tests of heterogeneity (I^2 and Cochrane's Q) can
231 be misleading when sample sizes are large and CIs are therefore narrow.²⁸ For studies that reported
232 estimates for all-cause adverse events and those deemed to be potentially related to cannabis use, we
233 preferentially synthesized results for all adverse events.

234 For analyses for which we observed high clinical heterogeneity (i.e., substantial differences in the
235 estimates of individual studies and minimal overlap in the confidence intervals), we presented results
236 narratively.

237 We classified adverse events as serious based on the classification used in primary studies.

238 We performed tests of interaction to establish whether subgroups differed significantly from one
239 another. We assessed the credibility of significant subgroup effects (test of interaction $p < 0.05$) using
240 published criteria.^{29 30}

241 We performed all analyses using the 'meta' package in R (version 3.5.1, R Foundation for Statistical
242 Computing).³¹

243 ***Certainty of evidence***

244 We used the GRADE approach to rate the certainty of evidence.^{32 33} Based on GRADE guidance for using
245 the ROBINS-I tool, evidence starts at high certainty and is downgraded by one level when the majority of
246 the evidence comes from studies at moderate risk of bias, two levels when the majority of the evidence
247 comes from studies at high risk of bias, and three levels when the majority of the evidence comes from
248 studies rated at critical risk of bias.³² We additionally considered potential limitations due to indirectness
249 if the population, intervention, or adverse events assessed in studies did not reflect the populations,
250 interventions, or adverse events of interest, inconsistency if there was important unexplained
251 differences in the results of studies, and imprecision if the upper and lower bounds of confidence
252 intervals indicated appreciably different rates of adverse events. For assessing inconsistency and
253 imprecision for the outcome all adverse events, based on feedback from the guideline panel, we
254 deemed a 20% difference in the prevalence of all adverse evidence to be patient-important; a 10%
255 difference for adverse events leading to discontinuation, serious adverse events, and psychiatric,
256 cognitive, withdrawal and dependence, injuries; and a 3% difference for potentially fatal adverse events,
257 such as suicides and motor vehicle accidents. We followed GRADE guidance for communicating our
258 findings.³⁴ Guideline panel members interpreted the magnitude of adverse events and decided whether
259 the observed prevalence of adverse events was sufficient to affect patients' decisions to use medical
260 cannabis or cannabinoids for chronic pain.

261 **Results**

262 ***Study selection***

263 Our search yielded 17,178 unique records of which 39 were eligible for review (Figure 1, Appendix 3).³⁵⁻
264 ⁷³ Appendix 4 presents studies excluded at the full-text screening stage and accompanying reasons for
265 exclusion.

266 **Description of studies**

267 Studies included 12,143 adults living with chronic pain and included a median of 100 (IQR 34 to 361)
268 participants (Table 1). Most studies (30/39; 76.9%) were longitudinal in design. Eighteen studies (46.2 %)
269 were conducted in Western Europe, fourteen (35.9%) in North America, six (15.4%) in Israel, and two
270 (5.1%) in the United Kingdom. Ten studies (25.6%) were funded by industry alone or industry in
271 combination with government and institutional funds; the remainder were funded either by
272 governments, institutions, or not-for-profit organizations (n=9; 23.1%), did not receive funds (n=3;
273 7.7%), or did not report funding information (n=17; 43.6%).

274 Thirty studies (76.9%) reported on people living with chronic non-cancer pain, eight (n=20.5%) with
275 mixed cancer and non-cancer chronic pain, and one (2.6%) with chronic cancer pain. All studies reported
276 on adults. Sixteen studies reported on mixed types of herbal cannabis (e.g., buds for smoking,
277 vaporizing, and ingesting, hashish, oils, extracts, edibles), nine on palmitoylethanolamide (PEA), four
278 each on nabiximols and dronabinol, two on nabilone, one each on Trokie lozenges and extracts, and four
279 did not report the type of medical cannabis used. One study reported on three types of medical
280 cannabis (dronabinol, nabiximols, and mixed herbal) separately. The median duration of medical
281 cannabis use was 24 weeks (IQR 12.0 to 33.8 weeks). Two studies were comparative: one study
282 compared nabilone with gabapentin and another compared herbal cannabis with standard care.^{39 48}
283 Studies reported a total of 525 unique adverse events.

284 **Risk of bias**

285 Appendix 5 presents the risk of bias of included studies. We rated all results at critical risk of bias except
286 for the comparative results from two studies,^{39 48} which were rated at serious and moderate risk of bias.
287 The primary limitation across studies was inadequate control for potential confounding either due to the
288 absence of a control group or inadequate adjustment for confounders. A third of studies were rated at
289 serious risk of bias for selection bias, primarily because they included prevalent users of medical
290 cannabis. Such studies may underestimate the incidence of adverse events since patients that
291 experience adverse events are more likely to discontinue medical cannabis early. Such studies may also
292 include adverse events that may have been present at inception and that are unrelated to medical
293 cannabis use.

294 ***All adverse events***

295 Twenty longitudinal and two cross-sectional studies, including 4,108 patients, reported the number of
296 patients experiencing one or more adverse events.^{36-43 46 47 54 56-60 62 64 65 69 70 73} Seven studies reported on
297 PEA, five on mixed herbal cannabis, three each on nabilone and nabiximols, two on dronabinol, and one
298 each on extracts and Trokie lozenges. The median duration of medical cannabis use was 24 weeks [IQR
299 12 to 32]. We observed substantial unexplained heterogeneity and so summarize the results
300 descriptively (Appendices 6 to 9). The prevalence of any adverse event ranged between 0% to 92.1%.
301 Studies with less than 24 weeks of cannabis use typically reported fewer adverse events than those with
302 more than 24 weeks. Patients using PEA experienced no adverse events. The evidence was overall very
303 uncertain due to risk of bias and inconsistency.

304 One study suggested that nabilone may reduce the risk of adverse events compared to gabapentin (-
305 13.1%; 95% CI -26.2 to 0), but the certainty of evidence was very low due to risk of bias and imprecision
306 (Table 2).

307 ***Adverse events leading to discontinuation***

308 Twenty longitudinal studies, including 6,509 patients, reported on the number of patients that
309 discontinued medical cannabis or cannabinoids due to adverse events.^{37 39 41-44 46-49 52 54 56 57 59 62 63 65 70 73}
310 Eight studies reported on PEA, four studies on mixed herbal cannabis, three on nabiximols, two on
311 nabilone, and one each on dronabinol and extracts, and one study did not report the type of medical
312 cannabis used by patients. The median duration of cannabis use was 24 weeks [IQR 8.6 to 32]. We
313 observed substantial unexplained heterogeneity and so summarize the results descriptively (Appendices
314 10 to 12). The prevalence of discontinuations due to adverse events ranged between 0% to 27.0%.
315 Studies with less than 24 weeks of cannabis use typically reported fewer discontinuations than those
316 with more than 24 weeks. Patients using PEA experienced no adverse events. The evidence was overall
317 very uncertain due to risk of bias and inconsistency.

318 One study suggested herbal cannabis may increase the risk of adverse events leading to discontinuation
319 compared to standard care without cannabis (4.7%; 95% CI 1.8 to 7.5). Another study suggested that
320 nabilone may reduce the risk of adverse events leading to discontinuation compared to gabapentin (-
321 9.4%; 95% CI -18.5 to -0.2). The certainty of evidence was low to very low due to risk of bias and
322 imprecision.

323 ***Serious adverse events***

324 Twenty-two longitudinal and two cross-sectional studies, including 4,273 patients, reported on the
325 number of patients experiencing one or more serious adverse events.^{35-37 39-43 46 48 49 52 54-60 62 65 70 71 73} Eight
326 studies reported on mixed herbal cannabis, eight on PEA, two each on nabilone and nabiximols each,
327 and one study each on dronabilon, extracts, and Trokie lozenges, and one study did not report the type
328 of cannabis used. The median duration of medical cannabis or cannabinoid use was 24 weeks (IQR 12 to
329 32), and few patients experienced serious adverse events (1.2%; 95% CI 0.1 to 3.1; $I^2=91%$) (Figure 2)
330 (Appendices 13 to 15). There was a statistically significant subgroup effect across different types of
331 medical cannabis though serious adverse events appeared consistently uncommon among different
332 types (low credibility). The certainty of evidence was very low overall due to serious risk of bias.

333 One study suggested herbal cannabis increased the risk of serious adverse events compared to standard
334 care without cannabis (1.5%; 95% CI -8.3 to 20.2). Another study found use of nabilone vs. gabapentin
335 showed no difference in the risk of serious adverse events. The certainty of evidence was low to very
336 low for both studies due to risk of bias and imprecision.

337 ***Psychiatric adverse events***

338 Eleven longitudinal and two cross-sectional studies, including 6,600 patients, reported on any psychiatric
339 adverse events, including psychiatric disorders, suicide, suicidal thoughts, depression, mania,
340 hallucinations, delusions, paranoia, anxiety, and euphoria (Appendices 16 to 25).^{35-37 43 47 48 60 63 67 68 70} Five
341 studies reported on mixed herbal cannabis, four on nabiximols, one each on dronabinol, nabilone, and
342 mixed types and one study did not specify the type of medical cannabis. The median duration of
343 cannabis use across studies was 52 weeks (IQR 20 to 52). Approximately one in seven medical cannabis
344 users experienced one or more psychiatric disorders or adverse events (13.5%; 95% CI 2.6 to 30.6;
345 $I^2=98%$). The most frequently occurring psychiatric adverse events were paranoia (5.6%; 9% CI 0 to 19.2;
346 $I^2=85%$) and anxiety (7.4%; 95% CI 0 to 26.9; $I^2=99%$). The certainty of evidence was very low due to risk
347 of bias, inconsistency (for psychiatric disorders and paranoia), and imprecision (for psychiatric disorder,
348 paranoia, and anxiety).

349 One study suggested that herbal cannabis may result in a trivial to moderate increase in the risk for
350 psychiatric disorders, mania, hallucinations, depression, paranoia, anxiety, and euphoria and a reduction
351 in the risk for suicides and delusions, compared with standard care without cannabis, though the
352 certainty of evidence was low to very low due to risk of bias and imprecision.

353 ***Cognitive and attentional adverse events***

354 Eleven longitudinal studies, including 6,257 patients, reported on cognitive adverse events, including
355 memory impairment, confusion, disorientation, and impaired attention (Appendices 26 to 29).^{35-37 43 47 48}

356 ^{60 63 67 68 70} Five studies reported on herbal cannabis, three on nabiximols, three on mixed types of
357 cannabis, and one each on dronabinol and nabilone. The median duration of cannabis use was 52 weeks
358 (IQR 24 to 52). The prevalence of cognitive adverse events ranged from 1.6% (95% CI 0.6 to 3.0; $I^2=88\%$)
359 to 5.3% (95% CI 2.1 to 9.6; $I^2=96\%$) for disorientation and memory impairment, respectively. The
360 certainty of evidence was very low due to risk of bias.

361 One study suggests herbal cannabis may slightly increase the risk for memory impairment and
362 disturbances in attention compared to standard care without cannabis, but reduce the risk for
363 confusion, though the certainty of evidence was low to very low due to risk of bias and imprecision.

364 ***Accidents and injuries***

365 One longitudinal study, including 431 patients, reported on accidents and injuries in patients using
366 mixed herbal cannabis for 52 weeks (Appendices 30 & 31).⁴⁸ This study suggests herbal cannabis used
367 for medical purposes may slightly increase the risk of motor vehicle accidents (0.5%; 95% CI -0.4 to 1.4)
368 but may not increase the risk of falls (0%; 95% CI -2.8 to 2.9). The certainty of evidence was low due to
369 risk of bias.

370 ***Dependence and withdrawal***

371 Four longitudinal and one cross-sectional study, including 2,248 patients, reported on dependence-
372 related adverse events, including dependence (one study reported on 'abuse' based on unspecified
373 criteria, one study reported on 'problematic use' using the Alcohol Use Disorder and Associated
374 Disabilities Interview Schedule–Diagnostic and Statistical Manual of Mental Disorders–Fourth Edition
375 (AUDADIS-IV)⁷⁴, and one study reported on 'dependence' using the Alcohol, Smoking, and Substance
376 Involvement Screening Test⁷⁵), withdrawal symptoms (defined as one or moderate or severe withdrawal
377 symptoms including sleep difficulties, anxiety, irritability, and appetite disturbance), and withdrawal
378 syndrome (two studies that used unspecified criteria) (Appendices 32 to 34).^{48 53 56 67 70} Two studies
379 reported on herbal cannabis, one each on nabiximols and nabilone, and one did not specify type of
380 medical cannabis used by patients. Follow-up ranged from 12 to 52 weeks. Though dependence and
381 withdrawal syndrome were uncommon with a prevalence of 4.4% (95% CI 0.0 to 19.9; $I^2=99\%$) and 2.1%

382 (95% CI 0 to 8.2; $I^2=89\%$), respectively, withdrawal symptoms were common (67.8%; 95% CI 64.1 to
383 71.4). The certainty of evidence was very low due to risk of bias, inconsistency, imprecision (for
384 dependence), and indirectness due to definitions of outcomes in studies were too vague to confidently
385 distinguish between dependence, addiction, withdrawal symptoms, and withdrawal syndrome.

386 One study suggested that herbal cannabis compared to standard care may slightly increase the risk of
387 withdrawal syndrome (0.5%; 95% CI -0.4 to 1.4) but the certainty of evidence was low due to risk of bias.

388 **Discussion**

389 ***Main findings***

390 Our systematic review and meta-analysis provides evidence that adverse events are common among
391 people living with chronic pain who use medical cannabis or cannabinoids, with approximately one in
392 four experiencing at least one adverse event—though the certainty of evidence is very low and the true
393 prevalence of adverse events may be substantially different. In contrast, serious adverse events, adverse
394 events leading to discontinuation, cognitive adverse events, accidents and injuries, and dependence and
395 withdrawal syndrome are uncommon. We compared studies with <24 weeks and ≥ 24 weeks cannabis
396 use and found more adverse events reported among studies with longer follow-up. This may be
397 explained by increased tolerance (tachyphylaxis) with prolonged exposure, necessitating increases in
398 dosage with consequent increased risk of harms. PEA, compared to other formulations of medical
399 cannabis, may result in the fewest adverse events. Though adverse events appear to be common, few
400 patients discontinued medical cannabis due to adverse events suggesting that most adverse events are
401 transient and/or outweighed by perceived benefits.

402 Our review represents the most comprehensive review of evidence from non-randomized studies
403 addressing adverse events of medical cannabis or cannabinoid use in people living with chronic pain.
404 While several previous reviews have summarized the evidence on short-term and common adverse
405 events of medical cannabis reported in randomized trials, such as oral discomfort, dizziness, and
406 headaches, our review focuses on serious and rare adverse events—the choice of which was informed
407 by a panel including patients, clinicians, and methodologists—and non-randomized studies, which can
408 follow larger numbers of patients for longer periods of time and thus may detect adverse events that
409 are infrequent or that are associated with longer durations of cannabis use.^{10 76-80} A parallel systematic
410 review of evidence from randomized controlled trials found no evidence to inform long-term harms of
411 medical cannabis as no eligible trial followed patients for more than 5.5 months.¹¹ One previously

412 published review that included non-randomized studies searched the literature until 2007, included
413 studies exploring medical cannabis for any indication (excluding synthetic cannabinoids) of which only
414 two enrolled people living with chronic pain.¹² The review also did not synthesize adverse event data
415 from non-randomized studies.¹² Unlike previous reviews, we focused exclusively on medical cannabis for
416 chronic pain and excluded recreational cannabis, because cannabis used for recreational purposes often
417 contains higher concentrations of tetrahydrocannabinol (THC) than medical cannabis. We also focused
418 on chronic pain because this patient population may be susceptible to different adverse events.
419 Depression and anxiety, for example, are commonly occurring comorbidities of chronic pain, which may
420 be exacerbated by cannabis.¹⁵⁻¹⁷

421 ***Strengths and limitations***

422 Strengths of this systematic review and meta-analysis include a comprehensive search for non-
423 randomized studies, explicit eligibility criteria, screening of studies and collection of data in duplicate to
424 increase reliability, and use of the GRADE approach to evaluate the certainty of evidence.

425 Our review is limited by the non-comparative design of most studies, which precludes confident
426 inferences regarding the proportion of adverse events that can be attributed to medical cannabis or
427 cannabinoids and the magnitude by which medical cannabis may increase or decrease the risk of
428 adverse events compared to other pain management options. Though adverse events appear common
429 among medical cannabis users, it is possible that other management options for chronic pain,
430 particularly opioids, may be associated with more (and more severe) adverse events.⁸¹ Partly due to the
431 non-comparative design of most studies, nearly all results included in our review were at serious or
432 critical risk of bias for confounding, either due to the absence of a control group or due to insufficient
433 adjustment for important confounders. Further, a third of studies were at high risk of selection bias,
434 primarily because they included prevalent cannabis users. In such studies, the prevalence of adverse
435 events may be underestimated. Our review provides limited evidence on the harms of medical cannabis
436 beyond one year of use since most studies reported adverse events for less than one year of follow-up.

437 We observed some inconsistency for many adverse events of interest and substantial inconsistency for
438 all adverse events and adverse events leading to discontinuation. We downgraded the certainty of
439 evidence when we observed important inconsistency and we did not present estimates from meta-
440 analyses for all adverse events and adverse events leading to discontinuation due to substantial
441 inconsistency.

442 Sixteen of 39 studies reported on herbal medical cannabis, some of which were consumed by smoking
443 or vaporizing, and may be associated with different adverse events (e.g. respiratory) than other
444 formulations of medical cannabis. We attempted to perform subgroup analyses based on the type of
445 medical cannabis. Results for subgroups, however, lacked credibility due to inconsistency and/or
446 imprecision.

447 Clinicians and patients may be more inclined to use medical cannabis or cannabinoids for pain relief if
448 adverse events are mild; however, the evidence on whether adverse events are transient, life
449 threatening, or the extent to which they impact quality of life is limited. While more than half of studies
450 reported on the proportion of adverse events that were serious, criteria for ascertaining severity were
451 rarely reported. None of the included studies reported the duration for which patients experienced
452 adverse events. Further, most primary studies did not report adequate details on methods for the
453 ascertainment of adverse events, including definitions or diagnostic criteria. The two studies that
454 reported on withdrawal syndrome, for example, did not provide diagnostic criteria.^{48 56} However, the
455 DSM-5 requires ≥ 3 of 7 withdrawal symptoms to be present within a week of stopping cannabis use to
456 meet a diagnosis of cannabis withdrawal syndrome.⁸² It is therefore reasonable that people living with
457 chronic pain that use medical cannabis would be more likely to experience withdrawal symptoms vs.
458 withdrawal syndrome.

459 While children and youth account for approximately 15% of all chronic pain patients, we did not identify
460 any evidence addressing the harms of medical cannabis in this population.⁸³ As such, the extent to which
461 our findings are generalizable to pediatric populations is uncertain. Although there is evidence that
462 cannabis use during youth is associated with increased risk of acute psychotic disorders, particularly
463 acute psychosis,⁸⁴ such studies have explored use of recreational cannabis that contains greater
464 amounts of THC than is typically seen in medical preparations. Further, the population of patients with
465 chronic pain on which the studies report may not be representative of all patients with chronic pain—
466 particularly rare conditions that cause chronic pain.

467 Finally, we excluded studies from meta-analyses when they did not explicitly report the adverse events
468 of interest to our panel members. This may have overestimated the prevalence of adverse events if the
469 adverse events of interest were not observed in the studies in which they were not reported. This was,
470 however, not possible to confirm because methods for the collection and reporting of adverse event

471 data across studies were variable (e.g., active monitoring vs. passive surveillance; collecting data on
472 specific adverse events vs. all adverse events) and poorly described in study reports.

473 ***Implications***

474 Our systematic review and meta-analysis shows that evidence regarding long-term and serious harms of
475 medical cannabis or cannabinoids is insufficient—an issue with important implications for patients and
476 clinicians considering this management option for chronic pain. While the evidence suggests that
477 adverse events are common in patients using medical cannabis for chronic pain, serious adverse events
478 appear uncommon, which suggests that the potential benefits of medical cannabis or cannabinoids
479 (although very modest) may outweigh potential harms for some patients.^{11 21}

480 Clinicians and patients considering medical cannabis should be aware that more adverse events were
481 reported among studies with longer follow-up, necessitating long term follow-up of patients and re-
482 evaluation of pain treatment options. Our findings also have implications for the choice of medical
483 cannabis. We found PEA, for example, to consistently be associated with few or no adverse events
484 across studies, though the evidence on the efficacy of PEA is limited.¹¹

485 We found very limited evidence comparing medical cannabis or cannabinoids with other pain
486 management options. Other pharmacological treatments for chronic pain, such as gabapentinoids,
487 antidepressants, and opioids, may be associated with more (and more serious) adverse events.⁸⁵⁻⁸⁷ To
488 guide patients' and clinicians' decisions on medical cannabis for chronic pain, future research should
489 compare the harms of medical cannabis and cannabinoids with other pain management options,
490 including opioids, ideally beyond one year of use, and adjust results for confounders. Future research
491 could also explore whether the harms of medical cannabis vary depending on the type of chronic pain.

492 Our review highlights the need for standardization of reporting of adverse events in non-randomized
493 studies since such studies represent a critical source of data on long-term and infrequently occurring
494 harms. To enhance the interpretability of adverse event data, future studies should also report the
495 duration and severity of adverse events, since these factors are important to patients' decisions.

496 A valuable output of our systematic review is an open-source database of over 500 unique adverse
497 events reported to date in non-randomized studies of medical cannabis or cannabinoids for chronic pain
498 with corresponding assessments of risk of bias. This database was compiled in duplicate by trained and
499 calibrated data extractors and is freely available to those interested in further analyzing the prevalence

500 of different types of adverse or to those interested in expanding the database to include adverse events
501 in patients using medical cannabis or cannabinoids for other indications.

502 **Conclusion**

503 Our systematic review and meta-analysis found very low certainty evidence that suggests that adverse
504 events are common among people living with chronic pain using medical cannabis or cannabinoids, but
505 that serious adverse events, adverse events causing discontinuation, cognitive adverse events, motor
506 vehicle accidents, falls, and dependence and withdrawal syndrome are uncommon. We also found very
507 low certainty evidence that longer duration of use was associated more adverse events and that PEA,
508 compared with other types of medical cannabis, may result in few or no adverse events. Future research
509 should compare the risks of adverse events of medical cannabis and cannabinoids with alternative pain
510 management options, including opioids, and adjust for potential confounders.

Table 1: Study characteristics

Study	Design	Country	Condition	Cannabis/ comparator	Dose	# of participants	Duration of cannabis use (weeks)
Ware, 2003 ³⁵	cross-sectional*	Canada	mixed non-cancer pain	mixed herbal	frequency: rarely (n=9), weekly (n=8), daily (n=5), >once daily (n=7) dose: 1-2 puffs (n=4), 3-4 puffs (n=13), whole joint (n=8), more than one joint (n=4)	32	NR
Lynch, 2006 ³⁶	longitudinal*	Canada	mixed non-cancer pain	mixed herbal	mean: 2.5 g/day	30	mean: 94.4
Rog, 2007 ³⁷	longitudinal*	UK	multiple sclerosis	nabiximols	mean: 7.5 sprays/day	63	66.1
Weber, 2009 ³⁸	longitudinal*†	Germany	mixed non-cancer pain	dronabinol	median: 7.5 mg/day	172	mean: 31
Bestard, 2011 ³⁹	longitudinal*	Canada	peripheral neuropathic pain	nabilone	mean: 3.0 mg/day	104	24
				gabapentin	mean: 2.3 g/day	107	
Fiz, 2011 ⁴⁰	cross-sectional*	Spain	fibromyalgia	mixed herbal	~1 to 2 cigarettes or spoonful daily (n=12) once every 2 to 4 days (n=5), less than twice a week (n=3), or occasionally (n=8)	28	<52 (n=11), 52 to 156 (n=9), >156 weeks (n=8)
Dominguez, 2012 ⁴¹	longitudinal*	Spain	lumbosciatica	PEA	300 mg bid	64	4
Gatti, 2012 ⁴²	longitudinal††	Italy	mixed cancer and non-cancer pain	PEA	600 mg bid three weeks; 600 mg/day for four weeks	564	7
Toth, 2012 ⁴³	longitudinal*†	Canada	diabetic peripheral neuropathy	nabilone	mean: 2.85 mg/day	37	4
Schifilliti, 2014 ⁴⁴	longitudinal††	Italy	diabetic neuropathy	PEA	300 mg bid	30	8.6
Storr, 2014 ⁴⁵	cross-sectional*	Canada	Crohn's disease (n=42), ulcerative colitis (n=10), indeterminate colitis (n=4)	mixed herbal	NR	56	<4 (n=3), 4 to 24 (n=9), 24 to 52 (n=5), >52 (n=32)
Del Giorno, 2015 ⁴⁶	longitudinal††	Italy	fibromyalgia	PEA	600 mg bid first month; 300 mg bid in the next 2 months	35	12
Hoggart, 2015 ⁴⁷	longitudinal††	UK, Czech Republic, Romania, Belgium, Canada	diabetic neuropathy	nabiximols	median: 6 to 8 sprays/day	380	median: 35.6
Ware, 2015 ⁴⁸	longitudinal*†	Canada	mixed non-cancer pain	mixed herbal	median: 2.5 g/day	215	52

				standard care		216	
Haroutounian, 2016 ⁴⁹	longitudinal*	Israel	mixed cancer and non-cancer pain	mixed herbal	mean: 43.2 g/month	206	30
Bellnier, 2017 ⁵⁰	longitudinal*	US	mixed cancer and non-cancer pain	mixed herbal	Capsule: 10 mg /8 to 10 hours Vapor pen inhaler for breakthrough pain: 2 mg THC, 0.1 mg CBD; 1 to 5 puffs every 15 minutes until pain relief; could be used every 4 to 6 hours	29	12
Cranford, 2017 ⁵¹	cross-sectional*	US	mixed non-cancer pain	NR	0 (n=69), <1/8 oz/week (n=130), 1/8 to 1/4 oz/week (n=156), 1/4 to 1/2 oz/week (n=179), 1/2 to 1 oz/week (n=122), 1 or more oz/week (n=115)	775	NR
Fanelli, 2017 ⁵²	longitudinal††	Italy	mixed cancer and non-cancer pain	mixed herbal	mean: 69.5 mg/day bediol; 67.0 mg/day bedrocan	341	mean: 14.01
Feingold, 2017 ⁵³	cross-sectional*	Israel	mixed cancer and non-cancer pain	mixed herbal	NR	406	NR
Paladini, 2017 ⁵⁴	longitudinal††	Italy	failed back surgery syndrome	PEA	600 mg bid for one month; 600 mg/day for one month	35	8
Passavanti, 2017 ⁵⁵	longitudinal††	Italy	lower back pain	PEA	600 mg bid	30	24
Schimrigk, 2017 ⁵⁶	longitudinal*†	Germany, Austria	multiple sclerosis	dronabinol	range: 7.5 to 15 mg/day	209	32
Chirchiglia, 2018 ⁵⁷	longitudinal††	Italy	lower back pain	PEA	1.2 g/day	100	4
Crowley, 2018 ⁵⁸	longitudinal*	US	mixed non-cancer pain	Trokie lozenges	NR	35	4 to 60
Habib, 2018 ⁵⁹	longitudinal*	Israel	fibromyalgia	mixed herbal	mean: 26 g/month	26	mean: 41.6
Anderson, 2019 ⁶⁰	longitudinal*	US	cancer pain	mixed herbal	NR	1120	16
Bonar, 2019 ⁶¹	cross-sectional††	US	mixed non-cancer pain	NR	0 (n=95), <1/8 oz/week (n=126), 1/8 to 1/4 oz/week (n=158), 1/4 to 1/2 oz/week (n=174), 1/2 to 1 oz/week (n=119), 1 or more oz/week (n=119)	790	NR
Cervigni, 2019 ⁶²	longitudinal†	Italy	interstitial cystitis/bladder pain syndrome	PEA	400 mg m-PEA plus 40 mg polydatin bid for 3 months, od for 3 months	32	24
Cremer-Schaeffer, 2019 ⁶³	longitudinal††	Germany	mixed cancer and non-cancer pain	dronabinol	NR	2017	52
				mixed herbal	NR	656	
				nabixim ols	NR	393	
Lejczak, 2019 ⁶⁴	longitudinal†	France	mixed cancer and non-cancer pain	dronabinol	range: 2.5 to 30 mg/day	148	range: 4 to 24 weeks
Loi, 2019 ⁶⁵	longitudinal*	Italy	endometriosis	PEA	600 mg/bid for 10 days; 400 mg m-PEA plus 40 mg polydatin bid	28	12.9
Naftali, 2019 ⁶⁶	longitudinal*	Israel	inflammatory bowel disease	mixed herbal	mean: 31 g/month	127	median: 176

					mean: 21 g/day THC; 170 g/day CBD		
Perron, 2019 ⁶⁷	cross-sectional*	US	mixed non-cancer pain	NR	daily (n=580), weekly (n=85)	618	≥12
Sagy, 2019 ⁶⁸	longitudinal††	Israel	mixed cancer and non-cancer pain	mixed herbal	median: 1000 mg/day cannabis	239	24
Sinclair, 2019 ⁶⁹	cross-sectional*	Australia	endometriosis	mixed herbal	median: 140 mg/day THC; 39 mg/day CBD less than once per week (n=12), once per week (n=6), two to six times per week (n=9), daily or multiple times per day (n=21)	48	NR
Ueberall, 2019 ⁷⁰	longitudinal*	Germany	low back pain (n=234), failed back surgery syndrome (n=148), shoulder/neck pain (n=91), post-herpetic neuralgia (n=72), peripheral diabetic neuropathy (n=56), brachial plexus injury (n=48), lumbar spinal stenosis (n=38), cancer (n=31), fibromyalgia (n=26), peripheral/focal nerve lesions (n=22), phantom pain (n=19), osteoarthritis (n=15)	nabiximols	mean: 7.1 sprays/day	800	12
Vigil, 2017 ⁷¹	longitudinal*	US	mixed non-cancer pain	NR	NR	37	mean: 82.4
Yassin, 2019 ⁷²	longitudinal††	Israel	fibromyalgia	mixed herbal	20 to 30 g/month	31	24
Giorgi, 2020 ⁷³	longitudinal††	Italy	fibromyalgia	extracts	10 to 30 drops/day; no more than 120 drops/day	102	24

NR=not reported

*Patient-report

†Clinician-report

††NR

513

514

515

Table 2: Prevalence of adverse events from non-comparative studies

Outcome	Number of studies	Number of participants	Duration of follow-up (weeks)	Prevalence % (95% CI)	I ² (%)	Certainty	Reasons for downgrading
All adverse events	22	4,108	4 to 94	The prevalence of adverse events ranged between 0% to 92.1%. Studies with less than 24 weeks of cannabis use typically reported fewer adverse events than those with more than 24 weeks. Patients using PEA experienced no adverse events. The evidence was overall very uncertain due to risk of bias and inconsistency.		very low	risk of bias (3 levels), inconsistency
Adverse events causing discontinuation	20	6,509	4 to 66	The prevalence of discontinuations due to adverse events ranged between 0% to 27.0%. Studies with less than 24 weeks of cannabis use typically reported fewer discontinuations than those with more than 24 weeks. Patients using PEA experienced no adverse events. The evidence was overall very uncertain due to risk of bias and inconsistency.		very low	risk of bias (3 levels), inconsistency
Serious adverse events	24	4,273	4 to 94	1.2 (0.1 to 3.1)	91	very low	risk of bias (3 levels)
Psychiatric adverse events							
Psychiatric disorder	4	1,458	12 to 66	13.5 (2.6 to 30.6)	98	very low	risk of bias (3 levels), inconsistency, imprecision
Suicide	1	215	52	0 (0 to 0.8)	NA	very low	risk of bias (3 levels)
Suicidal thoughts	1	3,066	52	0.1 (0 to 0.5)	44	very low	risk of bias (3 levels)
Depression	6	4,144	12 to 66	1.7 (0.9 to 2.7)	71	very low	risk of bias (3 levels)
Mania	1	215	52	0.5 (0 to 2)	NA	very low	risk of bias (3 levels)
Hallucinations	6	3,583	24 to 66	0.5 (0.1 to 1.3)	69	very low	risk of bias (3 levels)
Delusions	4	3,281	52	0.4 (0.2 to 0.6)	0	very low	risk of bias (3 levels)
Paranoia	3	277	52 to 94; one cross-sectional study	5.6 (0 to 19.2)	85	very low	risk of bias (3 levels), inconsistency, imprecision

Anxiety	5	1,695	12 to 94; two cross-sectional studies	7.4 (0 to 26.9)	99	very low	risk of bias (3 levels), imprecision
Euphoria	7	4,501	4 to 66	2.1 (0.9 to 3.8)	96	very low	risk of bias (3 levels)
Cognitive adverse events							
Memory impairment	6	4,484	4 to 176	5.3 (2.1 to 9.6)	96	very low	risk of bias (3 levels)
Confusion	7	1,654	4 to 176	1.8 (0.3 to 4.2)	81	very low	risk of bias (3 levels)
Disorientation	6	4,485	12 to 52	1.6 (0.6 to 3.0)	88	very low	risk of bias (3 levels)
Attention disorder or deficit	8	5,477	12 to 82	3.4 (1.3 to 6.3)	95	very low	risk of bias (3 levels)
Accidents and injuries							
Falls	1	215	52	2.3 (0.7 to 4.9)	NA	very low	risk of bias (3 levels)
Motor vehicle accidents	1	215	52	0.5 (0 to 2.0)	NA	very low	risk of bias (3 levels)
Dependence and withdrawal							
Dependence	3	1,824	12; one cross-sectional study	4.4 (0.0 to 19.9)	99	very low	risk of bias (3 levels), inconsistency, imprecision, indirectness
Withdrawal syndrome	2	424	32 to 52	2.1 (0 to 8.2)	89	very low	risk of bias (3 levels), indirectness
Withdrawal symptoms	1	618	NA; cross-sectional	67.8 (64.1 to 71.4)	NA	very low	risk of bias (3 levels), indirectness

Table 3: Risk differences for adverse events from comparative studies

Outcome	Exposure	Number of studies	Number of participants	Follow-up (weeks)	Risk with cannabis (/1000)	Risk with comparator (/1000)	Risk difference (95% CI)	Certainty	Reasons for downgrading
All adverse events	Nabilone vs. gabapentin	1	220	24	404	534	-13.1% (-26.2 to 0)	Very low	Risk of bias (2 levels), imprecision
Adverse events causing discontinuation	Herbal cannabis vs. standard care	1	431	52	47	0	4.7% (1.8 to 7.5)	Low	Risk of bias (2 levels),
	Nabilone vs. gabapentin	1	220	24	96	190	-9.4% (-18.5 to -0.2)	Very low	Risk of bias (2 levels), imprecision
Serious	Herbal cannabis vs. standard care	1	431	52	130	194	1.5% (-8.3 to 20.2) *	Low	Risk of bias, imprecision
	Nabilone vs. gabapentin	1	220	24	0	0	0% (0 to 0)	Very low	Risk of bias (2 levels), imprecision
Psychiatric disorder	Herbal cannabis vs. standard care	1	431	52	219	97	16.9% (5.8 to 40.5) †	Very low	Risk of bias (2 levels), imprecision
Suicide	Herbal cannabis vs. standard care	1	431	52	0	5	-0.5% (-1.4 to 0.4)	Low	Risk of bias (2 levels)
Mania	Herbal cannabis vs. standard care	1	431	52	5	0	0.5% (-0.4 to 1.4)	Low	Risk of bias (2 levels)
Hallucinations	Herbal cannabis vs. standard care	1	431	52	5	0	0.5% (-0.4 to 1.4)	Low	Risk of bias (2 levels)
Delusions	Herbal cannabis vs. standard care	1	431	52	0	5	-0.5% (-1.4 to 0.4)	Low	Risk of bias (2 levels)
Depression	Herbal cannabis vs. standard care	1	431	52	47	46	0.1% (-4 to 4)	Low	Risk of bias (2 levels)
Paranoia	Herbal cannabis vs. standard care	1	431	52	9	0	0.9% (-0.4 to 2.2)	Low	Risk of bias (2 levels)
Anxiety	Herbal cannabis vs. standard care	1	431	52	47	9	3.8% (0.6 to 6.8)	Low	Risk of bias (2 levels)
Euphoria	Herbal cannabis vs. standard care	1	431	52	42	0	4.2% (1.5 to 6.9)	Low	Risk of bias (2 levels)


Memory impairment	Herbal cannabis vs. standard care	1	431	52	19	0	1.9% (0.1 to 3.7)	Low	Risk of bias (2 levels)
Confusion	Herbal cannabis vs. standard care	1	431	52	14	19	-0.5% (-2.8 to 1.9)	Low	Risk of bias (2 levels)
Disturbance in attention	Herbal cannabis vs. standard care	1	431	52	23	9	1.4% (-1 to 3.8)	Low	Risk of bias (2 levels)
Falls	Herbal cannabis vs. standard care	1	431	52	23	23	0% (-2.8 to 2.9)	Low	Risk of bias (2 levels)
Motor vehicle accidents	Herbal cannabis vs. standard care	1	431	52	5	0	0.5% (-0.4 to 1.4)	Low	Risk of bias (2 levels)
Withdrawal syndrome	Herbal cannabis vs. standard care	1	431	52	5	0	0.5% (-0.4 to 1.4)	Very low	Risk of bias (2 levels),

* Risk difference calculated from adjusted incident rate ratio reported in study.

† Risk difference calculated from unadjusted incident rate ratio reported in study.

516 **Figures**

517 **Figure 1: Study selection process**




536

537

538

539

540 **Figure 2: Forest plot of the meta-analysis for all adverse events stratified by type of medical cannabis**



541

542

543

544 **References**

- 545 1. Mills SEE, Nicolson KP, Smith BH. Chronic pain: a review of its epidemiology and associated factors in
546 population-based studies. *Br J Anaesth* 2019;123(2):e273-e83. doi: 10.1016/j.bja.2019.03.023
547 [published Online First: 2019/05/14]
- 548 2. Mills SEE, van Hecke O, Smith BH. Handbook of Pain and Palliative Care: Biopsychosocial and
549 Environmental Approaches for the Life Course. 2019.
- 550 3. Keyhani S, Steigerwald S, Ishida J, et al. Risks and Benefits of Marijuana Use: A National Survey of U.S.
551 Adults. *Ann Intern Med* 2018;169(5):282-90. doi: 10.7326/m18-0810 [published Online First:
552 2018/07/25]
- 553 4. Dai H, Richter KP. A National Survey of Marijuana Use Among US Adults With Medical Conditions,
554 2016-2017. *JAMA Netw Open* 2019;2(9):e1911936. doi: 10.1001/jamanetworkopen.2019.11936
555 [published Online First: 2019/09/21]
- 556 5. National Academies of Sciences E, Medicine, Health, et al. The National Academies Collection: Reports
557 funded by National Institutes of Health. The Health Effects of Cannabis and Cannabinoids: The
558 Current State of Evidence and Recommendations for Research. Washington (DC): National
559 Academies Press (US)
- 560 Copyright 2017 by the National Academy of Sciences. All rights reserved. 2017.
- 561 6. Carr D, Schatman M. Cannabis for Chronic Pain: Not Ready for Prime Time. *American Journal of Public*
562 *Health* 2019;109(1):50-51. doi: 10.2105/AJPH.2018.304593 [published Online First: 2019/01/]
- 563 7. Ziemianski D, Capler R, Tekanoff R, et al. Cannabis in medicine: a national educational needs
564 assessment among Canadian physicians. *BMC Med Educ* 2015;15:52. doi: 10.1186/s12909-015-
565 0335-0 [published Online First: 2015/04/19]
- 566 8. Kahan M, Srivastava A. Is there a role for marijuana in medical practice? No. *Can Fam Physician*
567 2007;53(1):22-5. [published Online First: 2007/09/18]
- 568 9. Ware MA. Is there a role for marijuana in medical practice? Yes. *Can Fam Physician* 2007;53(1):22-5.
569 [published Online First: 2007/09/18]
- 570 10. Deshpande A, Mailis-Gagnon A, Zoheiry N, et al. Efficacy and adverse effects of medical marijuana
571 for chronic noncancer pain: Systematic review of randomized controlled trials. *Can Fam*
572 *Physician* 2015;61(8):e372-81. [published Online First: 2015/10/28]
- 573 11. Wang L, Hong P, May C, et al. Medical cannabis for chronic pain: a systematic review and meta-
574 analysis of randomized clinical trials. *BMJ* 2020;Submitted
- 575 12. Wang T, Collet JP, Shapiro S, et al. Adverse effects of medical cannabinoids: a systematic review.
576 *Cmaj* 2008;178(13):1669-78. doi: 10.1503/cmaj.071178 [published Online First: 2008/06/19]
- 577 13. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for Medical Use: A Systematic Review and
578 Meta-analysis. *Jama* 2015;313(24):2456-73. doi: 10.1001/jama.2015.6358 [published Online
579 First: 2015/06/24]
- 580 14. Hill KP, Hurley-Welljams-Dorof WM. Low to moderate quality evidence demonstrates the potential
581 benefits and adverse events of cannabinoids for certain medical indications. *Evid Based Med*
582 2016;21(1):17. doi: 10.1136/ebmed-2015-110264 [published Online First: 2015/10/23]
- 583 15. Bair MJ, Robinson RL, Katon W, et al. Depression and pain comorbidity: a literature review. *Arch*
584 *Intern Med* 2003;163(20):2433-45. doi: 10.1001/archinte.163.20.2433 [published Online First:
585 2003/11/12]
- 586 16. Magni G, Marchetti M, Moreschi C, et al. Chronic musculoskeletal pain and depressive symptoms in
587 the National Health and Nutrition Examination. I. Epidemiologic follow-up study. *Pain*
588 1993;53(2):163-8. doi: 10.1016/0304-3959(93)90076-2 [published Online First: 1993/05/01]

- 589 17. Wilson KG, Eriksson MY, D'Eon JL, et al. Major depression and insomnia in chronic pain. *Clin J Pain*
590 2002;18(2):77-83. doi: 10.1097/00002508-200203000-00002 [published Online First:
591 2002/03/08]
- 592 18. Siemieniuk RA, Agoritsas T, Macdonald H, et al. Introduction to BMJ Rapid Recommendations. *Bmj*
593 2016;354:i5191. doi: 10.1136/bmj.i5191 [published Online First: 2016/09/30]
- 594 19. Zeng L, Lytvyn L, Wang X, et al. Values and preferences towards medical cannabis among patients
595 with chronic pain: A mixed methods systematic review. *BMJ* 2020;Submitted
- 596 20. Noori A, Miroshnychenko A, Shergill Y, et al. Opioid-Sparing effects of medical cannabis for chronic
597 pain: A systematic review and meta-analysis of randomized and observational studies. *BMJ*
598 2020;Submitted
- 599 21. Busse J, Vankrunkelsven P, Zeng L, et al. Medical cannabis for chronic pain: a clinical practice
600 guideline. *BMJ* 2020;Submitted.
- 601 22. Zorzela L, Loke YK, Ioannidis JP, et al. PRISMA harms checklist: improving harms reporting in
602 systematic reviews. *Bmj* 2016;352:i157. doi: 10.1136/bmj.i157 [published Online First:
603 2016/02/03]
- 604 23. Busse JW, Bartlett SJ, Dougados M, et al. Optimal Strategies for Reporting Pain in Clinical Trials and
605 Systematic Reviews: Recommendations from an OMERACT 12 Workshop. *J Rheumatol*
606 2015;42(10):1962-70. doi: 10.3899/jrheum.141440 [published Online First: 2015/05/17]
- 607 24. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised
608 studies of interventions. *Bmj* 2016;355:i4919. doi: 10.1136/bmj.i4919 [published Online First:
609 2016/10/14]
- 610 25. Freeman MF, Tukey JW. Transformations related to the angular and the square root. *The Annals of*
611 *Mathematical Statistics* 1950:607-11.
- 612 26. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Controlled clinical trials* 1986;7(3):177-88.
- 613 27. Murad M, Montori V, Ioannidis J, et al. Fixed-effects and random-effects models. *Users' guide to the*
614 *medical literature A manual for evidence-based clinical practice McGraw-Hill, 3rd ed New York,*
615 *America* 2015
- 616 28. Rücker G, Schwarzer G, Carpenter JR, et al. Undue reliance on I(2) in assessing heterogeneity may
617 mislead. *BMC Med Res Methodol* 2008;8:79. doi: 10.1186/1471-2288-8-79 [published Online
618 First: 2008/11/28]
- 619 29. Sun X, Briel M, Walter SD, et al. Is a subgroup effect believable? Updating criteria to evaluate the
620 credibility of subgroup analyses. *Bmj* 2010;340:c117. doi: 10.1136/bmj.c117 [published Online
621 First: 2010/04/01]
- 622 30. Schandelmaier S, Briel M, Varadhan R, et al. Development of the Instrument to assess the Credibility
623 of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses.
624 *Cmaj* 2020;192(32):E901-e06. doi: 10.1503/cmaj.200077 [published Online First: 2020/08/12]
- 625 31. Schwarzer G. meta: An R package for meta-analysis. *R news* 2007;7(3):40-45.
- 626 32. Schünemann HJ, Cuello C, Akl EA, et al. GRADE guidelines: 18. How ROBINS-I and other tools to
627 assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of
628 evidence. *J Clin Epidemiol* 2019;111:105-14. doi: 10.1016/j.jclinepi.2018.01.012 [published
629 Online First: 2018/02/13]
- 630 33. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence
631 and strength of recommendations. *Bmj* 2008;336(7650):924-6. doi:
632 10.1136/bmj.39489.470347.AD [published Online First: 2008/04/26]
- 633 34. Santesso N, Glenton C, Dahm P, et al. GRADE guidelines 26: informative statements to communicate
634 the findings of systematic reviews of interventions. *J Clin Epidemiol* 2020;119:126-35. doi:
635 10.1016/j.jclinepi.2019.10.014 [published Online First: 2019/11/13]

- 636 35. Ware MA, Doyle CR, Woods R, et al. Cannabis use for chronic non-cancer pain: results of a
637 prospective survey. *Pain* 2003;102(1-2):211-6.
- 638 36. Lynch ME, Young J, Clark AJ. A case series of patients using medicinal marijuana for management of
639 chronic pain under the Canadian Marijuana Medical Access Regulations. *Journal of Pain &*
640 *Symptom Management* 2006;32(5):497-501.
- 641 37. Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for
642 neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year
643 extension trial. *Clinical Therapeutics* 2007;29(9):2068-79.
- 644 38. Weber J, Schley M, Casutt M, et al. Tetrahydrocannabinol (Delta 9-THC) treatment in chronic central
645 neuropathic pain and fibromyalgia patients: Results of a multicenter survey. *Anesthesiology*
646 *Research and Practice* 2009;2009 (no pagination)(827290) doi:
647 <http://dx.doi.org/10.1155/2009/827290>
- 648 39. Bestard JA, Toth CC. An open-label comparison of nabilone and gabapentin as adjuvant therapy or
649 monotherapy in the management of neuropathic pain in patients with peripheral neuropathy.
650 *Pain Practice* 2011;11(4):353-68. doi: <https://dx.doi.org/10.1111/j.1533-2500.2010.00427.x>
- 651 40. Fiz J, Duran M, Capella D, et al. Cannabis use in patients with Fibromyalgia: Effect on symptoms relief
652 and health-related quality of life. *PLoS ONE* 2011;6 (4) (no pagination)(e18440) doi:
653 <http://dx.doi.org/10.1371/journal.pone.0018440>
- 654 41. Domínguez CM, Martín AD, Ferrer FG, et al. N-palmitoylethanolamide in the treatment of
655 neuropathic pain associated with lumbosciatica. *Pain Manag* 2012;2(2):119-24. doi:
656 10.2217/pmt.12.5 [published Online First: 2012/03/01]
- 657 42. Gatti A, Lazzari M, Gianfelice V, et al. Palmitoylethanolamide in the treatment of chronic pain caused
658 by different etiopathogenesis. *Pain Medicine* 2012;13(9):1121-30. doi:
659 <https://dx.doi.org/10.1111/j.1526-4637.2012.01432.x>
- 660 43. Toth C, Mawani S, Brady S, et al. An enriched-enrolment, randomized withdrawal, flexible-dose,
661 double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in
662 the treatment of diabetic peripheral neuropathic pain. *Pain* 2012;153(10):2073-82. doi:
663 <http://dx.doi.org/10.1016/j.pain.2012.06.024>
- 664 44. Schifilliti C, Cucinotta L, Fedele V, et al. Micronized palmitoylethanolamide reduces the symptoms of
665 neuropathic pain in diabetic patients. *Pain Res Treat* 2014;2014:849623. doi:
666 10.1155/2014/849623 [published Online First: 2014/05/08]
- 667 45. Storr M, Devlin S, Kaplan GG, et al. Cannabis use provides symptom relief in patients with
668 inflammatory bowel disease but is associated with worse disease prognosis in patients with
669 Crohn's disease. *Inflammatory Bowel Diseases* 2014;20(3):472-80. doi:
670 <https://dx.doi.org/10.1097/01.MIB.0000440982.79036.d6>
- 671 46. Del Giorno R, Skaper S, Paladini A, et al. Palmitoylethanolamide in Fibromyalgia: Results from
672 Prospective and Retrospective Observational Studies. *Pain and Therapy* 2015;4(2):169-78. doi:
673 <http://dx.doi.org/10.1007/s40122-015-0038-6>
- 674 47. Hoggart B, Ratcliffe S, Ehler E, et al. A multicentre, open-label, follow-on study to assess the long-
675 term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the
676 management of neuropathic pain. *Journal of Neurology* 2015;262(1):27-40. doi:
677 <https://dx.doi.org/10.1007/s00415-014-7502-9>
- 678 48. Ware MA, Wang T, Shapiro S, et al. Cannabis for the Management of Pain: Assessment of Safety
679 Study (COMPASS). *Journal of Pain* 2015;16(12):1233-42. doi:
680 <https://dx.doi.org/10.1016/j.jpain.2015.07.014>
- 681 49. Haroutounian S, Ratz Y, Ginosar Y, et al. The Effect of Medicinal Cannabis on Pain and Quality-of-Life
682 Outcomes in Chronic Pain: A Prospective Open-label Study. *Clinical Journal of Pain*
683 2016;32(12):1036-43.

- 684 50. Bellnier T, Brown G, Ortega T, et al. A preliminary evaluation of the efficacy, safety, and costs
685 associated with the treatment of chronic pain with medical marijuana in the elderly. *Consultant*
686 *Pharmacist* 2017;32 (10):597. doi: <http://dx.doi.org/10.4140/TCPn.2017.577>
- 687 51. Cranford JA, Arnedt JT, Conroy DA, et al. Prevalence and correlates of sleep-related problems in
688 adults receiving medical cannabis for chronic pain. *Drug & Alcohol Dependence* 2017;180:227-
689 33. doi: <https://dx.doi.org/10.1016/j.drugalcdep.2017.08.017>
- 690 52. Fanelli G, De Carolis G, Leonardi C, et al. Cannabis and intractable chronic pain: an explorative
691 retrospective analysis of Italian cohort of 614 patients. *Journal of pain research* 2017;10:1217-
692 24. doi: <https://dx.doi.org/10.2147/JPR.S132814>
- 693 53. Feingold D, Goor-Aryeh I, Bril S, et al. Problematic Use of Prescription Opioids and Medicinal
694 Cannabis Among Patients Suffering from Chronic Pain. *Pain Medicine* 2017;18(2):294-306. doi:
695 <https://dx.doi.org/10.1093/pm/pnw134>
- 696 54. Paladini A, Varrassi G, Bentivegna G, et al. Palmitoylethanolamide in the Treatment of Failed Back
697 Surgery Syndrome. *Pain Res Treat* 2017;2017:1486010. doi: 10.1155/2017/1486010 [published
698 Online First: 2017/09/07]
- 699 55. Passavanti MB, Fiore M, Sansone P, et al. The beneficial use of ultramicrozoned
700 palmitoylethanolamide as add-on therapy to Tapentadol in the treatment of low back pain: a
701 pilot study comparing prospective and retrospective observational arms. *BMC Anesthesiology*
702 2017;17(1):171. doi: <https://dx.doi.org/10.1186/s12871-017-0461-9>
- 703 56. Schimrigk S, Marziniak M, Neubauer C, et al. Dronabinol Is a Safe Long-Term Treatment Option for
704 Neuropathic Pain Patients. *European Neurology* 2017;78(5-6):320-29. doi:
705 <https://dx.doi.org/10.1159/000481089>
- 706 57. Chirchiglia D, Chirchiglia P, Signorelli F. Nonsurgical lumbar radiculopathies treated with
707 ultramicrozoned palmitoylethanolamide (umPEA): A series of 100 cases. *Neurologia i*
708 *Neurochirurgia Polska* 2018;52(1):44-47. doi: <https://dx.doi.org/10.1016/j.pjnns.2017.11.002>
- 709 58. Crowley K, de Vries ST, Moreno-Sanz G. Self-Reported Effectiveness and Safety of Trokie R Lozenges:
710 A Standardized Formulation for the Buccal Delivery of Cannabis Extracts. *Frontiers in*
711 *Neuroscience* 2018;12:564. doi: <https://dx.doi.org/10.3389/fnins.2018.00564>
- 712 59. Habib G, Artul S. Medical Cannabis for the Treatment of Fibromyalgia. *JCR: Journal of Clinical*
713 *Rheumatology* 2018;24(5):255-58. doi: <https://dx.doi.org/10.1097/RHU.0000000000000702>
- 714 60. Anderson SP, Zylla DM, McGriff DM, et al. Impact of medical cannabis on patient-reported symptoms
715 for patients with cancer enrolled in Minnesota's medical cannabis program. *Journal of Oncology*
716 *Practice* 2019;15(6):E338-E45. doi: <http://dx.doi.org/10.1200/JOP.18.00619>
- 717 61. Bonar EE, Cranford JA, Arterberry BJ, et al. Driving under the influence of cannabis among medical
718 cannabis patients with chronic pain. *Drug & Alcohol Dependence* 2019;195:193-97. doi:
719 <https://dx.doi.org/10.1016/j.drugalcdep.2018.11.016>
- 720 62. Cervigni M, Nasta L, Schievano C, et al. Micronized Palmitoylethanolamide-Polydatin Reduces the
721 Painful Symptomatology in Patients with Interstitial Cystitis/Bladder Pain Syndrome. *BioMed*
722 *Research International* 2019;2019 (no pagination)(9828397) doi:
723 <http://dx.doi.org/10.1155/2019/9828397>
- 724 63. Cremer-Schaeffer P, Schmidt-Wolf G, Broich K. [Cannabis medicines in pain management : Interim
725 analysis of the survey accompanying the prescription of cannabis-based medicines in Germany
726 with regard to pain as primarily treated symptom]. *Der Schmerz* 2019;33(5):415-23. doi:
727 <https://dx.doi.org/10.1007/s00482-019-00399-z>
- 728 64. Lejczak S, Rousselot H, Di Patrizio P, et al. Dronabinol use in France between 2004 and 2017. *Revue*
729 *Neurologique* 2019;175(5):298-304. doi: <https://dx.doi.org/10.1016/j.neurol.2018.07.011>
- 730 65. Loi ES, Pontis A, Cofelice V, et al. Effect of ultramicrozoned-palmitoylethanolamide and co-
731 micronizedpalmitoylethanolamide/polydatin on chronic pelvic pain and quality of life in

- 732 endometriosis patients: An open-label pilot study. *International Journal of Women's Health*
733 2019;11:443-49. doi: <http://dx.doi.org/10.2147/IJWH.S204275>
- 734 66. Naftali T, Bar-Lev Schleider L, Sklerovsky Benjaminov F, et al. Medical cannabis for inflammatory
735 bowel disease: real-life experience of mode of consumption and assessment of side-effects.
736 *European Journal of Gastroenterology & Hepatology* 2019;31(11):1376-81. doi:
737 <https://dx.doi.org/10.1097/MEG.0000000000001565>
- 738 67. Perron BE, Holt KR, Yeagley E, et al. Mental health functioning and severity of cannabis withdrawal
739 among medical cannabis users with chronic pain. *Drug & Alcohol Dependence* 2019;194:401-09.
740 doi: <https://dx.doi.org/10.1016/j.drugalcdep.2018.09.029>
- 741 68. Sagy I, Bar-Lev Schleider L, Abu-Shakra M, et al. Safety and Efficacy of Medical Cannabis in
742 Fibromyalgia. *Journal of Clinical Medicine* 2019;8(6):05. doi:
743 <https://dx.doi.org/10.3390/jcm8060807>
- 744 69. Sinclair J, Smith CA, Abbott J, et al. Cannabis Use, a Self-Management Strategy Among Australian
745 Women With Endometriosis: Results From a National Online Survey. *Journal of Obstetrics &*
746 *Gynaecology Canada: JOGC* 2020;42(3):256-61. doi:
747 <https://dx.doi.org/10.1016/j.jogc.2019.08.033>
- 748 70. Ueberall MA, Essner U, Mueller-Schwefe GHH. Effectiveness and tolerability of THC:CBD oromucosal
749 spray as add-on measure in patients with severe chronic pain: Analysis of 12-week open-label
750 real-world data provided by the German pain e-registry. *Journal of Pain Research* 2019;12:1577-
751 604. doi: <http://dx.doi.org/10.2147/JPR.S192174>
- 752 71. Vigil JM, Stith SS, Adams IM, et al. Associations between medical cannabis and prescription opioid
753 use in chronic pain patients: A preliminary cohort study. *PLoS ONE [Electronic Resource]*
754 2017;12(11):e0187795. doi: <https://dx.doi.org/10.1371/journal.pone.0187795>
- 755 72. Yassin M, Oron A, Robinson D. Effect of adding medical cannabis to analgesic treatment in patients
756 with low back pain related to fibromyalgia: an observational cross-over single centre study.
757 *Clinical & Experimental Rheumatology* 2019;37 Suppl 116(1):13-20.
- 758 73. Giorgi V, Bongiovanni S, Atzeni F, et al. Adding medical cannabis to standard analgesic treatment for
759 fibromyalgia: a prospective observational study. *Clinical & Experimental Rheumatology* 2020;38
760 Suppl 123(1):53-59.
- 761 74. Grant BF, Dawson DA, Stinson FS, et al. The Alcohol Use Disorder and Associated Disabilities
762 Interview Schedule-IV (AUDADIS-IV): reliability of alcohol consumption, tobacco use, family
763 history of depression and psychiatric diagnostic modules in a general population sample. *Drug*
764 *Alcohol Depend* 2003;71(1):7-16. doi: 10.1016/s0376-8716(03)00070-x [published Online First:
765 2003/06/25]
- 766 75. Humeniuk R, Ali R. Validation of the Alcohol, Smoking and Substance Involvement Screening Test
767 (ASSIST) and pilot brief intervention: a technical report of phase II findings of the WHO ASSIST
768 Project. Validation of the alcohol, smoking and substance involvement screening test (ASSIST)
769 and pilot brief intervention: a technical report of phase II findings of the WHO ASSIST
770 Project2006.
- 771 76. Stockings E, Campbell G, Hall WD, et al. Cannabis and cannabinoids for the treatment of people with
772 chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and
773 observational studies. *Pain* 2018;159(10):1932-54. doi: 10.1097/j.pain.0000000000001293
774 [published Online First: 2018/05/31]
- 775 77. Allan GM, Finley CR, Ton J, et al. Systematic review of systematic reviews for medical cannabinoids:
776 Pain, nausea and vomiting, spasticity, and harms. *Can Fam Physician* 2018;64(2):e78-e94.
777 [published Online First: 2018/02/17]

- 778 78. Campeny E, López-Pelayo H, Nutt D, et al. The blind men and the elephant: Systematic review of
779 systematic reviews of cannabis use related health harms. *Eur Neuropsychopharmacol* 2020;33:1-
780 35. doi: 10.1016/j.euroneuro.2020.02.003 [published Online First: 2020/03/14]
- 781 79. Memedovich KA, Dowsett LE, Spackman E, et al. The adverse health effects and harms related to
782 marijuana use: an overview review. *CMAJ Open* 2018;6(3):E339-e46. doi:
783 10.9778/cmajo.20180023 [published Online First: 2018/08/18]
- 784 80. Nugent SM, Morasco BJ, O'Neil ME, et al. The Effects of Cannabis Among Adults With Chronic Pain
785 and an Overview of General Harms: A Systematic Review. *Ann Intern Med* 2017;167(5):319-31.
786 doi: 10.7326/m17-0155 [published Online First: 2017/08/15]
- 787 81. Els C, Jackson TD, Kunyk D, et al. Adverse events associated with medium- and long-term use of
788 opioids for chronic non-cancer pain: an overview of Cochrane Reviews. *Cochrane Database Syst*
789 *Rev* 2017;10(10):Cd012509. doi: 10.1002/14651858.CD012509.pub2 [published Online First:
790 2017/10/31]
- 791 82. Diagnostic and statistical manual of mental disorders : DSM-5. Arlington, VA: American Psychiatric
792 Association 2013.
- 793 83. Goodman JE, McGrath PJ. The epidemiology of pain in children and adolescents: a review. *Pain*
794 1991;46(3):247-64. doi: 10.1016/0304-3959(91)90108-a [published Online First: 1991/09/01]
- 795 84. Myles H, Myles N, Large M. Cannabis use in first episode psychosis: Meta-analysis of prevalence, and
796 the time course of initiation and continued use. *Aust N Z J Psychiatry* 2016;50(3):208-19. doi:
797 10.1177/0004867415599846 [published Online First: 2015/08/20]
- 798 85. Shanthanna H, Gilron I, Rajarathinam M, et al. Benefits and safety of gabapentinoids in chronic low
799 back pain: A systematic review and meta-analysis of randomized controlled trials. *PLoS Med*
800 2017;14(8):e1002369. doi: 10.1371/journal.pmed.1002369 [published Online First: 2017/08/16]
- 801 86. Ferraro MC, Bagg MK, Wewege MA, et al. Efficacy, acceptability, and safety of antidepressants for
802 low back pain: a systematic review and meta-analysis. *Syst Rev* 2021;10(1):62. doi:
803 10.1186/s13643-021-01599-4 [published Online First: 2021/02/26]
- 804 87. Busse JW, Craigie S, Juurlink DN, et al. Guideline for opioid therapy and chronic noncancer pain.
805 *Cmaj* 2017;189(18):E659-e66. doi: 10.1503/cmaj.170363 [published Online First: 2017/05/10]
- 806